Journal
ANTIVIRAL THERAPY
Volume 15, Issue -, Pages 9-15Publisher
INT MEDICAL PRESS LTD
DOI: 10.3851/IMP1523
Keywords
-
Categories
Funding
- Bristol-Myers Squibb
- Abbott Laboratories
- Gilead
- GlaxoSmithKline
- Johnson Johnson
- MSD
- Pfizer
- Boehringer-Ingelheim
- Roche
Ask authors/readers for more resources
Patients presenting late with HIV infection are at a higher risk of clinical events, are difficult to treat and have a higher mortality compared with those who present earlier. Indeed, being diagnosed too late for effective treatment has been shown to be a common scenario leading to death. The increased risk for opportunistic diseases and increased mortality are associated with low CD4(+) T-cell counts. In addition to the detrimental effect on the health of the individual, late presentation also creates a significant societal burden because it is associated with increased risk of HIV transmission and increased resource use. All of these factors highlight the benefit of earlier testing, diagnosis and treatment of HIV.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available